Osteoporosis in multiple sclerosis
Fractures resulting from osteoporosis are a major cause of morbidity and mortality in the developed world. People with multiple sclerosis experience reduced mobility and are susceptible to falls. Glucocorticoid use and reduced mobility are known risk factors for osteoporosis. This paper is a review...
Gespeichert in:
Veröffentlicht in: | Multiple Sclerosis Journal 2010-09, Vol.16 (9), p.1031-1043 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1043 |
---|---|
container_issue | 9 |
container_start_page | 1031 |
container_title | Multiple Sclerosis Journal |
container_volume | 16 |
creator | Hearn, Andrew P Silber, Eli |
description | Fractures resulting from osteoporosis are a major cause of morbidity and mortality in the developed world. People with multiple sclerosis experience reduced mobility and are susceptible to falls. Glucocorticoid use and reduced mobility are known risk factors for osteoporosis. This paper is a review of osteoporosis in people with multiple sclerosis, looking at its prevalence, risk factors and possible mechanisms. We also review management guidelines for osteoporosis in the general population and use these to propose guidelines for osteoporosis management amongst multiple sclerosis patients. A number of studies have examined the incidence of reduced bone mineral density amongst people with multiple sclerosis; the majority provide convincing evidence that bone mineral density is significantly reduced in multiple sclerosis patients. The most significant risk factors appear to arise from the chronic disease process of multiple sclerosis and not from glucocorticoid use. There are currently no guidelines or consensus as how best to treat osteoporosis amongst multiple sclerosis patients despite their being at an increased risk. We propose an algorithm for the screening and treatment of osteoporosis in people with multiple sclerosis. |
doi_str_mv | 10.1177/1352458510368985 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_877595118</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458510368985</sage_id><sourcerecordid>754014194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-6279485e6506a61f333904abc7afe07341515f8b3685ea057eae8853429684963</originalsourceid><addsrcrecordid>eNqFkMtLw0AQxhdRbK3ePUkpiKfoTHZnH0cp9QGFXvQctnEjKXmZTQ7-925stVAQTzvs_L5vZj7GLhFuEZW6Q06xIE0IXGqj6YiNUSgVgVFwHOrQjob-iJ15vwEApTidslEMFDRajtls5TtXN3Vb-9xP82pa9kWXN4Wb-rRw37_n7CSzhXcXu3fCXh8WL_OnaLl6fJ7fL6NUxNRFMlZGaHKSQFqJGefcgLDrVNnMgeICCSnT67ApOQuknHVaExexkVoYySfsZuvbtPVH73yXlLlPXVHYytW9T7RSZAhR_0sqEoACjQjk7IDc1H1bhTMSJQwXHGCwgy2Uhnt967KkafPStp8JQjLknBzmHCRXO99-Xbq3X8FPsAG43gHWp7bIWlulud9znCNIOXDRlvP23e2X-3PwFyeCjZ8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>749343008</pqid></control><display><type>article</type><title>Osteoporosis in multiple sclerosis</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Hearn, Andrew P ; Silber, Eli</creator><creatorcontrib>Hearn, Andrew P ; Silber, Eli</creatorcontrib><description>Fractures resulting from osteoporosis are a major cause of morbidity and mortality in the developed world. People with multiple sclerosis experience reduced mobility and are susceptible to falls. Glucocorticoid use and reduced mobility are known risk factors for osteoporosis. This paper is a review of osteoporosis in people with multiple sclerosis, looking at its prevalence, risk factors and possible mechanisms. We also review management guidelines for osteoporosis in the general population and use these to propose guidelines for osteoporosis management amongst multiple sclerosis patients. A number of studies have examined the incidence of reduced bone mineral density amongst people with multiple sclerosis; the majority provide convincing evidence that bone mineral density is significantly reduced in multiple sclerosis patients. The most significant risk factors appear to arise from the chronic disease process of multiple sclerosis and not from glucocorticoid use. There are currently no guidelines or consensus as how best to treat osteoporosis amongst multiple sclerosis patients despite their being at an increased risk. We propose an algorithm for the screening and treatment of osteoporosis in people with multiple sclerosis.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458510368985</identifier><identifier>PMID: 20551086</identifier><identifier>CODEN: MUSCFZ</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Accidental Falls ; Adult ; Aged ; Aged, 80 and over ; Algorithms ; Animals ; Biological and medical sciences ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Evidence-Based Medicine ; Female ; Fractures, Bone - epidemiology ; Fractures, Bone - etiology ; Fractures, Bone - prevention & control ; Humans ; Male ; Medical sciences ; Middle Aged ; Multiple Sclerosis - complications ; Multiple Sclerosis - epidemiology ; Multiple Sclerosis - therapy ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Neurology ; Osteoporosis ; Osteoporosis - complications ; Osteoporosis - diagnosis ; Osteoporosis - epidemiology ; Osteoporosis - therapy ; Practice Guidelines as Topic ; Predictive Value of Tests ; Prevalence ; Risk Assessment ; Risk Factors ; Treatment Outcome</subject><ispartof>Multiple Sclerosis Journal, 2010-09, Vol.16 (9), p.1031-1043</ispartof><rights>The Author(s) 2010</rights><rights>2015 INIST-CNRS</rights><rights>SAGE Publications © Sep 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-6279485e6506a61f333904abc7afe07341515f8b3685ea057eae8853429684963</citedby><cites>FETCH-LOGICAL-c425t-6279485e6506a61f333904abc7afe07341515f8b3685ea057eae8853429684963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458510368985$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458510368985$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>313,314,776,780,788,21798,27899,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23310666$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20551086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hearn, Andrew P</creatorcontrib><creatorcontrib>Silber, Eli</creatorcontrib><title>Osteoporosis in multiple sclerosis</title><title>Multiple Sclerosis Journal</title><addtitle>Mult Scler</addtitle><description>Fractures resulting from osteoporosis are a major cause of morbidity and mortality in the developed world. People with multiple sclerosis experience reduced mobility and are susceptible to falls. Glucocorticoid use and reduced mobility are known risk factors for osteoporosis. This paper is a review of osteoporosis in people with multiple sclerosis, looking at its prevalence, risk factors and possible mechanisms. We also review management guidelines for osteoporosis in the general population and use these to propose guidelines for osteoporosis management amongst multiple sclerosis patients. A number of studies have examined the incidence of reduced bone mineral density amongst people with multiple sclerosis; the majority provide convincing evidence that bone mineral density is significantly reduced in multiple sclerosis patients. The most significant risk factors appear to arise from the chronic disease process of multiple sclerosis and not from glucocorticoid use. There are currently no guidelines or consensus as how best to treat osteoporosis amongst multiple sclerosis patients despite their being at an increased risk. We propose an algorithm for the screening and treatment of osteoporosis in people with multiple sclerosis.</description><subject>Accidental Falls</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Algorithms</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Evidence-Based Medicine</subject><subject>Female</subject><subject>Fractures, Bone - epidemiology</subject><subject>Fractures, Bone - etiology</subject><subject>Fractures, Bone - prevention & control</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Sclerosis - complications</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Multiple Sclerosis - therapy</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Neurology</subject><subject>Osteoporosis</subject><subject>Osteoporosis - complications</subject><subject>Osteoporosis - diagnosis</subject><subject>Osteoporosis - epidemiology</subject><subject>Osteoporosis - therapy</subject><subject>Practice Guidelines as Topic</subject><subject>Predictive Value of Tests</subject><subject>Prevalence</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkMtLw0AQxhdRbK3ePUkpiKfoTHZnH0cp9QGFXvQctnEjKXmZTQ7-925stVAQTzvs_L5vZj7GLhFuEZW6Q06xIE0IXGqj6YiNUSgVgVFwHOrQjob-iJ15vwEApTidslEMFDRajtls5TtXN3Vb-9xP82pa9kWXN4Wb-rRw37_n7CSzhXcXu3fCXh8WL_OnaLl6fJ7fL6NUxNRFMlZGaHKSQFqJGefcgLDrVNnMgeICCSnT67ApOQuknHVaExexkVoYySfsZuvbtPVH73yXlLlPXVHYytW9T7RSZAhR_0sqEoACjQjk7IDc1H1bhTMSJQwXHGCwgy2Uhnt967KkafPStp8JQjLknBzmHCRXO99-Xbq3X8FPsAG43gHWp7bIWlulud9znCNIOXDRlvP23e2X-3PwFyeCjZ8</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>Hearn, Andrew P</creator><creator>Silber, Eli</creator><general>SAGE Publications</general><general>Sage Publications</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QP</scope></search><sort><creationdate>20100901</creationdate><title>Osteoporosis in multiple sclerosis</title><author>Hearn, Andrew P ; Silber, Eli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-6279485e6506a61f333904abc7afe07341515f8b3685ea057eae8853429684963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Accidental Falls</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Algorithms</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Evidence-Based Medicine</topic><topic>Female</topic><topic>Fractures, Bone - epidemiology</topic><topic>Fractures, Bone - etiology</topic><topic>Fractures, Bone - prevention & control</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Sclerosis - complications</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Multiple Sclerosis - therapy</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Neurology</topic><topic>Osteoporosis</topic><topic>Osteoporosis - complications</topic><topic>Osteoporosis - diagnosis</topic><topic>Osteoporosis - epidemiology</topic><topic>Osteoporosis - therapy</topic><topic>Practice Guidelines as Topic</topic><topic>Predictive Value of Tests</topic><topic>Prevalence</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hearn, Andrew P</creatorcontrib><creatorcontrib>Silber, Eli</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Multiple Sclerosis Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hearn, Andrew P</au><au>Silber, Eli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Osteoporosis in multiple sclerosis</atitle><jtitle>Multiple Sclerosis Journal</jtitle><addtitle>Mult Scler</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>16</volume><issue>9</issue><spage>1031</spage><epage>1043</epage><pages>1031-1043</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><coden>MUSCFZ</coden><abstract>Fractures resulting from osteoporosis are a major cause of morbidity and mortality in the developed world. People with multiple sclerosis experience reduced mobility and are susceptible to falls. Glucocorticoid use and reduced mobility are known risk factors for osteoporosis. This paper is a review of osteoporosis in people with multiple sclerosis, looking at its prevalence, risk factors and possible mechanisms. We also review management guidelines for osteoporosis in the general population and use these to propose guidelines for osteoporosis management amongst multiple sclerosis patients. A number of studies have examined the incidence of reduced bone mineral density amongst people with multiple sclerosis; the majority provide convincing evidence that bone mineral density is significantly reduced in multiple sclerosis patients. The most significant risk factors appear to arise from the chronic disease process of multiple sclerosis and not from glucocorticoid use. There are currently no guidelines or consensus as how best to treat osteoporosis amongst multiple sclerosis patients despite their being at an increased risk. We propose an algorithm for the screening and treatment of osteoporosis in people with multiple sclerosis.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>20551086</pmid><doi>10.1177/1352458510368985</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1352-4585 |
ispartof | Multiple Sclerosis Journal, 2010-09, Vol.16 (9), p.1031-1043 |
issn | 1352-4585 1477-0970 |
language | eng |
recordid | cdi_proquest_miscellaneous_877595118 |
source | MEDLINE; SAGE Complete |
subjects | Accidental Falls Adult Aged Aged, 80 and over Algorithms Animals Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Evidence-Based Medicine Female Fractures, Bone - epidemiology Fractures, Bone - etiology Fractures, Bone - prevention & control Humans Male Medical sciences Middle Aged Multiple Sclerosis - complications Multiple Sclerosis - epidemiology Multiple Sclerosis - therapy Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Neurology Osteoporosis Osteoporosis - complications Osteoporosis - diagnosis Osteoporosis - epidemiology Osteoporosis - therapy Practice Guidelines as Topic Predictive Value of Tests Prevalence Risk Assessment Risk Factors Treatment Outcome |
title | Osteoporosis in multiple sclerosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A44%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Osteoporosis%20in%20multiple%20sclerosis&rft.jtitle=Multiple%20Sclerosis%20Journal&rft.au=Hearn,%20Andrew%20P&rft.date=2010-09-01&rft.volume=16&rft.issue=9&rft.spage=1031&rft.epage=1043&rft.pages=1031-1043&rft.issn=1352-4585&rft.eissn=1477-0970&rft.coden=MUSCFZ&rft_id=info:doi/10.1177/1352458510368985&rft_dat=%3Cproquest_cross%3E754014194%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=749343008&rft_id=info:pmid/20551086&rft_sage_id=10.1177_1352458510368985&rfr_iscdi=true |